Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

Across the world, only a few dozen people appear to carry a genetic glitch that lets them brush off viruses that flatten ...

During viral reproduction, the influenza polymerase (top left, in blue) scans along the ribonucleoprotein helix to produce messenger RNA. Credit: Science Like a camera-shy teenager, influenza’s ...

The technology, called the Viral-Engineered RNA-based Activation System (VERAS), hijacks the virus's own replication ...